HVIVO PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.95 GBX | 0.00% |
|
-1.28% | +13.47% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- With a 2023 P/E ratio at 20.79 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +13.47% | 23Cr | - | ||
| +19.41% | 4.55TCr | B- | ||
| +38.65% | 3.94TCr | A | ||
| -8.62% | 3.85TCr | B | ||
| +26.95% | 3.07TCr | B | ||
| -13.50% | 2.6TCr | C | ||
| +10.74% | 2.59TCr | B- | ||
| +44.87% | 1.41TCr | B+ | ||
| +34.36% | 1.27TCr | C+ | ||
| -7.14% | 1.13TCr | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- VENN Stock
- Ratings hVIVO plc
